Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 110

Sort by

Sort Order Select

Journal Articles

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Kunhwa Kim, Dai Chihara, Luis E. Fayad, Sattva S. Neelapu, Sairah Ahmed, Frederick Hagemeister, Chijioke Nze, Swaminathan P Iyer, Preetesh Jain, Michael Wang, Paolo Strati, Fateeha Furqan, Ayushi Chauhan, Michael R. Green, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4511.1.

https://doi.org/10.1182/blood-2024-205196

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Eduardo Edelman Saul, Bryan Valcarcel, Amy A. Ayers, Mansoor Noorani, Dai Chihara, Fateeha Furqan, Sairah Ahmed, Swaminathan P Iyer, Sattva S. Neelapu, Luis E. Fayad, F. B. Hagemeister, Chijioke Nze, Preetesh Jain, Michael Wang, Paolo Strati, Ayushi Chauhan, Francisco Vega, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2024-211247

Published: 2024

Journal Articles

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Blood (2024) 144 (Supplement 1): 6420.

https://doi.org/10.1182/blood-2024-211482

Published: 2024

Journal Articles

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Strouse, Umar Farooq, Roni Shouval, Anusha Vallurupalli, Amy Moskop, Caron A. Jacobson, Frederick Locke, John H. Baird, Paolo Strati, Dilan A. Patel, Saurabh Dahiya, Michael T. Hemmer, Brad Du, Clare Spooner, Jenny J. Kim, Debbie L. Mirjah, Zhen-Huan Hu, Marcelo C. Pasquini, Yi Lin

Blood (2024) 144 (Supplement 1): 609.

https://doi.org/10.1182/blood-2024-207976

Published: 2024

Journal Articles

Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4508.

https://doi.org/10.1182/blood-2024-198053

Published: 2024

Journal Articles

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Blood (2024) 144 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2024-207616

Published: 2024

Journal Articles

Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma

Tony Z. Zhuang, Lei Feng, Dai Chihara, Chijioke Nze, Amy A. Ayers, Mansoor Noorani, James D. Ayres, Daniela E. Duenas, Kumudha Balakrishnan, Ekaterina Nesterenko, Mark Meerson, Ksenia Zornikova, Krystle Nomie, Nikita Kotlov, Nathan Fowler, Maria Alma Rodriguez, Sattva S. Neelapu, Christopher R. Flowers, Paolo Strati

Blood (2024) 144 (Supplement 1): 2982.

https://doi.org/10.1182/blood-2024-202654

Published: 2024

Journal Articles

Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Kunhwa Kim, Amy Ayers, Sairah Ahmed, Linda Claret, Paolo Strati, Ranjit Nair, Chijioke Nze, Jeremy Ramdial, Janet Torres, Elizabeth J. Shpall, Luis E. Fayad, Loretta Nastoupil, Jason R. Westin, Christopher R. Flowers, Sattva S. Neelapu, Dai Chihara

Blood (2024) 144 (Supplement 1): 5121.

https://doi.org/10.1182/blood-2024-211023

Published: 2024

Journal Articles

Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy

Neha Akkad, Amy Ayers, Kumudha Balakrishnan, Loretta Nastoupil, Dai Chihara, Luis Malpica, Paolo Strati, Ziyi Li, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2024-201804

Published: 2024

Journal Articles

Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy

Blood (2024) 144 (Supplement 1): 4377.

https://doi.org/10.1182/blood-2024-203844

Published: 2024

Journal Articles

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2024-208300

Published: 2024

Journal Articles

Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

Blood (2024) 144 (Supplement 1): 2377.

https://doi.org/10.1182/blood-2024-203753

Published: 2024

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood blood.2024025366.

https://doi.org/10.1182/blood.2024025366

Published: 2024

Includes: Supplemental data

Journal Articles

Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Gastric MALT Lymphoma

Jillian Gunther, Jie Xu, Manoop S Bhutani, Paolo Strati, Penny Fang, Susan Wu, Bouthaina S. Dabaja, Wenli Dong, Priya Bhosale, Christopher R. Flowers, Ranjit Nair, Luis Malpica, Preetesh Jain, Sattva S. Neelapu, Maria Alma Rodriguez, Dai Chihara, Loretta J. Nastoupil, Chelsea Camille Pinnix

Blood (2023) 142 (Supplement 1): 298.

https://doi.org/10.1182/blood-2023-181757

Published: 2023

Journal Articles

Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma

Jason Westin, Ranjit Nair, Luis Fayad, Swami P. Iyer, Luis Malpica, Sattva S. Neelapu, Felipe Samaniego, Raphael Eric Steiner, Paolo Strati, Shivon Mathew, Donna Griffith, Loretta J. Nastoupil, Wirt Montinez, Maria Alma Rodriguez, Frederick Hagemeister, Lei Feng, Francisco Vega, Christopher R. Flowers, Sairah Ahmed

Blood (2023) 142 (Supplement 1): 1721.

https://doi.org/10.1182/blood-2023-191123

Published: 2023

Journal Articles

Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416)

Paolo Strati, Tatyana Feldman, Christiane Querfeld, Salvia Jain, Nathanael McCurley, Rita Bàrcia, Koby Kidder, Jelle Kylstra

Blood (2023) 142 (Supplement 1): 4856.

https://doi.org/10.1182/blood-2023-175040

Published: 2023

Journal Articles

A Phase II Study of Loncastuximab Tesirine As Consolidation Strategy in Patients with LBCL in PR at Day 30 after CAR T-Cell Therapy

Ajlan Al Zaki, Lei Feng, Jason Westin, Ranjit Nair, Luis Fayad, Grace Watson, Sherry Adkins, Elizabeth J. Shpall, Mario L. Marques-Piubelli, Jared Henderson, Loretta J. Nastoupil, Christopher R. Flowers, Sairah Ahmed, Sattva S. Neelapu, Paolo Strati

Blood (2023) 142 (Supplement 1): 3098.

https://doi.org/10.1182/blood-2023-179004

Published: 2023

Journal Articles

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 856.

https://doi.org/10.1182/blood-2023-180381

Published: 2023

Journal Articles

Differing Inflammatory Profiles and Survival Outcomes of Cytokine Storm Arising from CAR T-Cell Therapy, COVID and Malignancy-Associated HLH in Patients with Hematological Malignancies

Blood (2023) 142 (Supplement 1): 3507.

https://doi.org/10.1182/blood-2023-187946

Published: 2023

Journal Articles

Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study

Paolo Strati, Lei Feng, Jason Westin, Ranjit Nair, Luis Fayad, Maria Alma Rodriguez, Dai Chihara, Luis Malpica, Jared Henderson, Mariana Gallardo, Mario L. Marques-Piubelli, Polina Turova, Aleksandr Zaitsev, Iris Wang, Christopher R. Flowers, Loretta J. Nastoupil, Sattva S. Neelapu

Blood (2023) 142 (Supplement 1): 983.

https://doi.org/10.1182/blood-2023-180762

Published: 2023

NARROW

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma

Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy

Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Gastric MALT Lymphoma

Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma

Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416)

A Phase II Study of Loncastuximab Tesirine As Consolidation Strategy in Patients with LBCL in PR at Day 30 after CAR T-Cell Therapy

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Differing Inflammatory Profiles and Survival Outcomes of Cytokine Storm Arising from CAR T-Cell Therapy, COVID and Malignancy-Associated HLH in Patients with Hematological Malignancies

Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only